Create a narrative

MediWound Community

NasdaqGM:MDWD Community

1 Narratives written by author
0 Comments on narratives written by author
3 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

Consensus Narrative from 6 Analysts

FDA Approval And Phase III Trial Will Expand Wound Care

Key Takeaways Strong EscharEx results and strategic partnerships boost potential sales growth, leveraging Medicare policies and Phase III trials for greater revenue prospects. NexoBrid's FDA approval and geographic expansion increase market opportunities, while new manufacturing capabilities aim to meet demand, supporting long-term revenue growth.

US$31.00

FV

37.3% undervalued

25.90%

Revenue growth p.a.

0

0

3

1 day ago